Maraviroc – a CCR5 antagonist for the treatment of HIV-1 infection [PDF]
Frontiers in Immunology, 2015 Despite the dramatic decline in human immunodeficiency virus type 1 (HIV-1)related morbidity and mortality following the discovery of the protease inhibitors and the advent of combination highly active antiretroviral (ARV) therapy in the mid1990s, many ...
Elna eVan Der Ryst
doaj +4 more sources
Evolution of coreceptor utilization to escape CCR5 antagonist therapy. [PDF]
Virology, 2016 The HIV-1 envelope interacts with coreceptors CCR5 and CXCR4 in a dynamic, multi-step process, its molecular details not clearly delineated. Use of CCR5 antagonists results in tropism shift and therapeutic failure. Here we describe a novel approach using
Zhang J +8 more
europepmc +3 more sources
Filling the Gaps in Antagonist CCR5 Binding, a Retrospective and Perspective Analysis [PDF]
Frontiers in Immunology, 2022 The large number of pathologies that position CCR5 as a central molecular determinant substantiates the studies aimed at understanding receptor-ligand interactions, as well as the development of compounds that efficiently block this receptor.
Yerkezhan Amerzhanova, Luca Vangelista
doaj +3 more sources
PLoS ONE, 2015 Objective To compare central nervous system (CNS) outcomes in participants treated during acute HIV infection with standard combination antiretroviral therapy (cART) vs. cART plus integrase inhibitor and CCR5 antagonist (cART+). Design 24-week randomized
Phanuphak, N +10 more
core +3 more sources
The Cytokine Nicotinamide Phosphoribosyltransferase (eNAMPT; PBEF; Visfatin) Acts as a Natural Antagonist of C-C Chemokine Receptor Type 5 (CCR5) [PDF]
Cells, 2020 (1) Background: Extracellular nicotinamide phosphoribosyltrasferase (eNAMPT) is released by various cell types with pro-tumoral and pro-inflammatory properties.
Simone Torretta +6 more
doaj +2 more sources
Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis. [PDF]
Int J Mol Sci, 2022 (1) Background: With new potential drug targets emerging, combination therapies appear attractive to treat non-alcoholic steatohepatitis (NASH) and fibrosis. Chemokine receptor CCR2/5 antagonists can improve fibrosis by reducing monocyte infiltration and
Puengel T +15 more
europepmc +2 more sources
CCR5 antagonist treatment inhibits vascular injury by regulating NADPH oxidase 1. [PDF]
Biochem Pharmacol, 2022 Background: Chemokine (C- Cmotif) ligand 5 (CCL5) and its receptor C-C motif chemokine receptor 5 (CCR5), have been broadly studied in conjunction with infectious pathogens, however, their involvement in cardiovascular disease is not completely ...
Singh S +3 more
europepmc +2 more sources
CCR5 Antagonist Maraviroc Inhibits Acute Exacerbation of Lung Inflammation Triggered by Influenza Virus in Cigarette Smoke-Exposed Mice. [PDF]
Pharmaceuticals (Basel), 2021 Influenza A virus (IAV) infection is a common cause of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Since macrophage inflammatory protein 1 α, a chemokine that acts through CC-chemokine receptor (CCR)-5, appears elevated in COPD
Ferrero MR +9 more
europepmc +2 more sources
CCR5 antagonist reduces HIV-induced amyloidogenesis, tau pathology, neurodegeneration, and blood-brain barrier alterations in HIV-infected hu-PBL-NSG mice. [PDF]
Mol Neurodegener, 2021 Neurocognitive impairment is present in 50% of HIV-infected individuals and is often associated with Alzheimer’s Disease (AD)-like brain pathologies, including increased amyloid-beta (Aβ) and Tau hyperphosphorylation.
Bhargavan B +3 more
europepmc +2 more sources
CCR5 antagonist blocks metastasis of basal breast cancer cells [PDF]
Cancer Research, 2012 The roles of the chemokine CCL5 and its receptor CCR5 in breast cancer progression remain unclear. Here, we conducted microarray analysis on 2,254 human breast cancer specimens and found increased expression of CCL5 and its receptor CCR5, but not CCR3 ...
Pestell, Timothy G. +6 more
core +2 more sources